2024 ILTS – ILCA Consensus Conference: Liver Transplantation for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

2024 ILTS – ILCA Consensus Conference: Liver Transplantation for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma is organized by K.I.T. Group GmbH Association & Conference Management, International Liver Transplantation Society (ILTS), International Liver Cancer Association (ILCA) and will be held from Feb 01 - 02, 2024 at ADEIT - Fundación Universidad - Company of the University of Valencia, Valencia, Spain.

Description:
Liver transplantation has become one of the mainstay treatments for selected patients with liver tumors. Based on the conclusions of the Consensus Conference held in Zurich in 2010, the last practice guideline on this topic was published in Lancet Oncology in 2012. Given the substantial changes in the management of liver tumors, as well as the advancements that have been made in the field of Transplant Oncology since 2010, there is a need to:
• Update the concepts discussed in the previous Consensus Conference.
• Identify unmet needs that will push the scientific community to improve the outcomes of patients with liver cancers.

The Consensus Conference will be a shared effort between the International Liver Cancer Association and the International Liver TransplantationSociety, both leading the management and guidelines in Transplant Oncology for primary liver cancer.

The appointed Working Groups comprised of experts in the field of liver transplantation will address the following main topics:
• How to select patients with HCC and iCCA for liver transplantation to optimize the outcomes.
• How to manage patients in the waiting list and which are the best neoadjuvant treatments.
• How to incorporate new therapies for both HCC and iCCA for patients undergoing liver transplantation.
• How to best manage post–transplant cancer recurrences after liver transplantation

Learning Objectives:
• Understand how to select patients for liver transplantation with HCC and iCCA
• Determine how to manage patients with HCC and iCCA before liver transplantation
• Determine how to incorporate new systematic and locoregional therapies for patients awaiting liver transplantation for HCC and iCCA.
• Understand the differences between DDLT and LDLT for patients with HCC and iCCA

Working Groups:
• Assessment of Candidates with HCC for Liver Transplantation
• Criteria for Listing Patients with HCC
• Immunotherapy and LT
• LDLT vs. DDLT
• Post–transplant Management
• The Role of LT for Intrahepatic Cholangiocarcinoma
• The Patient’s Perspective on Liver Transplantation for
• Hepatocellular Carcinoma and Intrahepatic Cholangi. ocarcinoma

Additional details will be posted as soon as information is available.